Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses: 2011-2018

Historic Other Accumulated Expenses for Vanda Pharmaceuticals (VNDA) over the last 4 years, with Mar 2018 value amounting to $2.0 million.

  • Vanda Pharmaceuticals' Other Accumulated Expenses rose 8.93% to $2.0 million in Q1 2018 from the same period last year, while for Mar 2018 it was $2.0 million, marking a year-over-year increase of 8.93%. This contributed to the annual value of $2.0 million for FY2017, which is 75.84% up from last year.
  • According to the latest figures from Q1 2018, Vanda Pharmaceuticals' Other Accumulated Expenses is $2.0 million, which was up 1.50% from $2.0 million recorded in Q4 2017.
  • Vanda Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $2.0 million for Q1 2018, and its period low was $614,000 during Q1 2014.
  • Its 3-year average for Other Accumulated Expenses is $1.6 million, with a median of $1.9 million in 2017.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Other Accumulated Expenses skyrocketed by 4,555.56% in 2014 and then plummeted by 32.66% in 2016.
  • Vanda Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $2.0 million in 2014, then declined by 16.63% to $1.7 million in 2015, then plummeted by 32.66% to $1.1 million in 2016, then soared by 75.84% to $2.0 million in 2017, then climbed by 8.93% to $2.0 million in 2018.
  • Its last three reported values are $2.0 million in Q1 2018, $2.0 million for Q4 2017, and $1.9 million during Q3 2017.